Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Cassava Drama
View:
Post by FarmerBetsy on Jan 22, 2025 7:57am

Cassava Drama

The drama continues after the stock tanking is the class action law suit. Acoording to the complaint, defendants provided investors and materila information concerning Cassava's leading drug candidate, sinufilam. Defendants' statements included, among other things, clear confidence in simufilam's ability to treat Alzheimer's Disease. Former Pormis chief medical officer James Kupeic is chief medical officer at Cassava
Comment by M101 on Jan 22, 2025 11:24am
I had a problem with their science presentation independent from the eventual fraud, the core hypothesis* was never fleshed out on the website as it is with Promis.    *"Simufilam’s primary mechanism is to disrupt the toxic signaling of soluble Aβ42 via the α7nAChR that hyperphosphorylates tau" https://www.mdpi.com/1422-0067/24/18/13927
ProMIS Neurosciences Inc